Literature DB >> 17977647

Cannibalism: a way to feed on metastatic tumors.

Stefano Fais1.   

Abstract

Cannibalism of tumors is an old story for pathologists, but it remained a mystery for at least one century. Recent data highlighted tumor cannibalism as a key advantage in tumor malignancy, possibly involved in resistance of tumors to the specific immune reaction. However, new data suggests also that metastatic tumor cells may use this peculiar function to feed in conditions of low nutrient supply. This makes malignant cancer cells more similar to microorganisms, rather than to normal cells undergoing malignant transformation. In cytological or histological samples of human tumors it is common to detect cells with one or many vacuoles, possibly containing cells under degradation, that push the nucleus to the periphery giving it the shape of a crescent moon. The cannibal cells may feed on sibling tumor cells, but also of the lymphocytes that should kill them. Cannibal cells eat everything without distinguishing between the feeding materials, with a mechanism that mostly differ from typical phagocytosis. Despite such phenomenon is considered mainly non-selective, a molecular framework of factors that contribute to cannibalism has been described. This machinery includes the presence of an acidic environment that allows a continuous activation of specific lytic enzymes, such as cathepsin B. Cannibalism occurs in apparently well defined structures whose main actors are big caveolar-like vacuoles and a connection between caveolin-1 and the actin cytoskeleton through the actin-linker molecule ezrin. Each of the components of the cannibal framework may represent specific tumor targets for future new strategies against cancer.

Entities:  

Mesh:

Year:  2007        PMID: 17977647     DOI: 10.1016/j.canlet.2007.09.014

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  53 in total

1.  Glutamine targeting inhibits systemic metastasis in the VM-M3 murine tumor model.

Authors:  Laura M Shelton; Leanne C Huysentruyt; Thomas N Seyfried
Journal:  Int J Cancer       Date:  2010-11-15       Impact factor: 7.396

2.  MFG-E8 expression for progression of oral squamous cell carcinoma and for self-clearance of apoptotic cells.

Authors:  Manabu Yamazaki; Satoshi Maruyama; Tatsuya Abé; Ahmed Essa; Hamzah Babkair; Jun Cheng; Takashi Saku
Journal:  Lab Invest       Date:  2014-09-29       Impact factor: 5.662

Review 3.  On the origin of cancer metastasis.

Authors:  Thomas N Seyfried; Leanne C Huysentruyt
Journal:  Crit Rev Oncog       Date:  2013

Review 4.  Cathepsin B as a cancer target.

Authors:  Christopher S Gondi; Jasti S Rao
Journal:  Expert Opin Ther Targets       Date:  2013-01-08       Impact factor: 6.902

5.  Aurora A orchestrates entosis by regulating a dynamic MCAK-TIP150 interaction.

Authors:  Peng Xia; Jinhua Zhou; Xiaoyu Song; Bing Wu; Xing Liu; Di Li; Shuyuan Zhang; Zhikai Wang; Huijuan Yu; Tarsha Ward; Jiancun Zhang; Yinmei Li; Xiaoning Wang; Yong Chen; Zhen Guo; Xuebiao Yao
Journal:  J Mol Cell Biol       Date:  2014-05-20       Impact factor: 6.216

6.  Nutrition, metabolism and colorectal cancer.

Authors:  G Misciagna; M G Caruso; M Trevisan
Journal:  Genes Nutr       Date:  2008-04       Impact factor: 5.523

7.  Identification of cardiac stem cells within mature cardiac myocytes.

Authors:  Galina Belostotskaya; Alexey Nevorotin; Michael Galagudza
Journal:  Cell Cycle       Date:  2015-08-17       Impact factor: 4.534

8.  Cancer as a metabolic disease.

Authors:  Thomas N Seyfried; Laura M Shelton
Journal:  Nutr Metab (Lond)       Date:  2010-01-27       Impact factor: 4.169

Review 9.  Perspectives on the mesenchymal origin of metastatic cancer.

Authors:  Leanne C Huysentruyt; Thomas N Seyfried
Journal:  Cancer Metastasis Rev       Date:  2010-12       Impact factor: 9.264

10.  Targeting of integrin beta1 and kinesin 2alpha by microRNA 183.

Authors:  Guorong Li; Coralia Luna; Jianming Qiu; David L Epstein; Pedro Gonzalez
Journal:  J Biol Chem       Date:  2009-11-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.